Zane Elfessi

Zane Elfessi

Auto-generated profile, based on publicly available information

Zane Elfessi

Department of Emergency Medicine, Jesse Brown Veterans Affairs Medical Center, Chicago, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 December 2024 in Environmental Science: Processes & Impacts
Verified
Journal Article
Closed access
PDF file
SFSaeed Farhoodi
Saeed Farhoodi
IKIn Sung Kang
In Sung Kang
YZYicheng Zeng
Yicheng Zeng
KJKaveeta Jagota
Kaveeta Jagota
NKNancy Karpen
Nancy Karpen
Brent StephensBrent Stephens
Brent Stephens
There is an increasing number of randomized clinical trials intended to assess the effectiveness of indoor air cleaners for improving participant outcomes in real-world settings. In this communication, we synthesize the current state of registered air cleaner intervention trials and call attention to the critical importance of conducting measurements to characterize the performance and in situ utilization of air cleaners in such trials to improve interpretation of exposure measurements and patient outcomes. We draw upon the existing literature and preliminary findings from our ongoing one-year, randomized, single-blind, placebo-controlled case-control trial of stand-alone air filtration in the homes of U.S. military Veterans to inform our recommendations. We demonstrate how to conduct industry-standard performance testing and how to use long-term measurements of air cleaner power draw to assess air cleaner operation. In our analysis of interim data from 53 homes to date with a mean data collection period of 275 days, we found that most air cleaners, whether active or sham, were operated predominantly at low or medium fan speeds, and most participants operated their air cleaner on predominantly one fan speed. In a few homes, air cleaners were mostly off. We estimate that air cleaner operation in these homes is providing a median additional equivalent particle loss rate of ∼0.7/h (ranging ∼0–2.8/h). Accordingly, we recommend that air cleaner intervention trials adopt the steps described herein to account for the amount of clean air delivered in real-world settings and to provide important context alongside indoor exposure measurements and analysis of patient outcomes.

1 December 2019 in The American Journal of Emergency Medicine
Verified
Journal Article
Closed access
ZEZane Elfessi
Zane Elfessi
ELErica Liu
Erica Liu
YDYelena Dukarevich
Yelena Dukarevich
KCKaylee Caniff
Kaylee Caniff
KMKatrina Marquez
Katrina Marquez
ZSZaheera Shabbir
Zaheera Shabbir

1 October 2018 in The American Journal of Emergency Medicine
Verified
Journal Article
Closed access
RDRichard J. Doyle
Richard J. Doyle
ZEZane Elfessi
Zane Elfessi
KKKevin Kolman
Kevin Kolman

25 January 2023 in Visual Journal of Emergency Medicine
Verified
Journal Article
Closed access
ZEZane Elfessi
Zane Elfessi
RDRichard Doyle
Richard Doyle
LYLisa Young
Lisa Young
MKMark Knaub
Mark Knaub
TYTravis Yamanaka
Travis Yamanaka

13 February 2026 in Journal of the American Pharmacists Association
Verified
Journal Article
Open access
NLNoah Lybik
Noah Lybik
BCBrian Cone
Brian Cone
SSSibe Skelton
Sibe Skelton
ZEZane Elfessi
Zane Elfessi
To report acute opioid withdrawal following abrupt cessation of high-dose 7-hydroxymitragynine (7-OH) in a patient who transitioned from kratom, and to outline pharmacist-focused assessment, management, and regulatory counseling strategies including a formal causality assessment. A 43-year-old male with opioid use disorder presented with nausea, diarrhea, abdominal cramping, restlessness, chills/clamminess, and anxiety after discontinuing concentrated 7-OH (360 mg/day; last 30 mg dose ∼48 hours prior). Vitals: BP 138/93 mmHg, T 37.7°C, HR 84 bpm, RR 16; pupils 2-3 mm; Clinical Opioid Withdrawal Scale (COWS) 5. He had transitioned from kratom to 7-OH ∼18 months earlier. He met DSM-5 criteria for moderate opiate use disorder, though he never engaged in formal treatment. The patient reported that he transitioned from kratom to concentrated 7-OH products because he perceived stronger, faster opioid-like effects and required smaller quantities to avoid withdrawal. ED management included buprenorphine/naloxone 4/1 mg SL, adjuncts (clonidine, ondansetron, loperamide, methocarbamol, NSAIDs, acetaminophen), counseling on precipitated withdrawal, and referral for treatment. A Naranjo assessment supported probable causality (score = 6). Concentrated 7-OH products differ from kratom leaf and can produce dependence and withdrawal; pharmacists should screen for these products, time buprenorphine initiation to moderate withdrawal, provide harm-reduction counseling, and incorporate evolving state regulations into patient education.

18 August 2025 in Advances in Therapy
Verified
Journal Article
Open access
PDF file
NSNadia Sweis
Nadia Sweis
ZEZane Z. Elfessi
Zane Z. Elfessi
IRIsrael Rubinstein
Israel Rubinstein
RCRachel Caskey
Rachel Caskey
Background Tobacco smoking remains a global public health challenge, contributing to preventable mortality and morbidity and imposing substantial burdens on health care costs. We investigated whether direct health care costs differ substantially between self-reported tobacco smokers and non-smokers. Methods This systematic literature review was conducted in accordance with PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. Medline PubMed, Embase, PubMed Central, and Scopus were searched to identify studies of direct health care costs between smokers and non-smokers for participants aged ≥18 years. All observational, prospective, retrospective, and non-randomized comparative studies were considered. Data extraction included mean annual health care costs (± SD) for both groups. Mean differences (MD) in annual health care costs between smokers and non-smokers, expressed in 2025 US dollars, were compared and adjusted for a 12-month period and inflated to 2025 using consumer price indices. Results Of 873 studies identified, 11 were included in quantitative synthesis, which compared 19,759,529 smokers with 206,913,108 non-smokers for direct health care costs. Mean age ranged from 34.5–60.6 years for smokers and 34.3–65.1 years for non-smokers. Mean annual health care costs ranged from $65,640–$1297.1 for smokers and $54,564–$724.4 for non-smokers. Annual incremental direct health care costs for smokers versus non-smokers ranged from –$458 (95% CI [confidence interval]: –2011.0 to 1,095.0) to $11,076 (95% CI: 10,211.9 to 11,940.1) in 2025 US dollars. Meta-analysis revealed smoking generally incurred greater health care costs than non-smoking, with a mean annual incremental cost of $1916.5 (95% CI: –439.9 to 4,272.9). The result was not statistically significant (MD = 1,916.5; p = 0.111). Substantial heterogeneity was observed (I2 = 99.9%). Sensitivity analysis excluding studies of chronic disease yielded a reduced incremental cost for the general population, with a statistically significant difference (MD = 583.9, p = 0.02), although heterogeneity remained high (I2 = 98.0%). Conclusion This meta-analysis supports the assertion that smoking substantially increases direct health care costs compared with non-smoking, particularly for the general population.